Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zepatier for Preemptive Treatment in HCV-positive to HCV-negative Cardiac Transplant
NCT03026023Phase 4Withdrawn
- Start
- Aug 2018
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of grazoprevir in hepatitis C (HCV). Planned start Aug 2018; status: withdrawn.
02
Drugs
grazoprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03026023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03026023.